Rachel is an intellectual property litigation partner at HGF and has worked with clients across a broad range of sectors including, life sciences, chemicals, food and beverage, aviation, media and telecommunications industries. Rachel has extensive experience of litigating before the Patents Court, as well as in patent and trade mark oppositions before the UKIPO, EPO and OHIM. Rachel also regularly advises in relation to pan-European IP strategy for both patent and trade mark proceedings.
Rachel has been involved in a number of decided cases before the Patents Court including: Nestec SA v Dualit Ltd  R.P.C. 32; Virgin Atlantic Airways v Air Canada & ors,  R.P.C. 10; Appeal  R.P.C 18; Actavis UK Ltd v Novartis AG  EWHC 41 (Ch); Actavis UK Ltd v Novartis AG  F.S.R. 18; Actavis UK Ltd v Eli Lilly & Co Ltd  EWCA Civ 43; Baxter Healthcare Corporation v Abbott Laboratories  EWHC 3185 (Pat); and Ranbaxy UK Ltd v Warner-Lambert Co.  F.S.R. 14.
Rachel joined HGF in 2015 after training and working at a leading international IP litigation practice for over 10 years.
Rachel has a BSc in Cell Biotechnology from the University of Alberta, Canada and a Masters in Health Care Ethics from the University of Leeds, UK. Rachel completed her Postgraduate Diploma in Law and LPC at the College of Law and further completed a Postgraduate Diploma in Intellectual Property at the University of Bristol UK.